ArticleIrish journal of medical science2023
Assessment of serum neopterin and calprotectin as biomarkers for subclinical inflammation in patients with familial Mediterranean fever.
Article in Irish journal of medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- The cally index as an indicator of inflammatory burden across clinical phases of familial mediterranean fever.Clinical rheumatology · 2026Article
- Practical considerations for monitoring patients with familial Mediterranean fever: review of evidence and expert opinion.Frontiers in immunology · 2026Review
- Association between serum neopterin level and diabetic peripheral neuropathy in patients with type 2 diabetes: a pilot observational study.Diabetology international · 2025Article
- miR-21 and cathepsin B in familial Mediterranean fever: novel findings regarding their impact on disease severity.BMJ paediatrics open · 2025Article
- Inflammatory biomarker analysis confirms reduced disease severity in heterozygous patients with familial Mediterranean fever.RMD open · 2024Article
- Exploring S100A8/A9, neopterin, and MMP3 in familial Mediterranean fever.Clinical and experimental immunology · 2024Article
- Role of serum calprotectin in identifying familial Mediterranean fever attacks.Irish journal of medical science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFamilial Mediterranean fever (FMF) is the most common autoinflammatory disease characterized by short, repeated, and self-limiting attacks of fever and serositis. Subclinical inflammation can persist in the periods with no symptoms and result in amyloidosis even with colchicine treatment. Neopterin and calprotectin have been considered essential players in inflammation and immune response.
aimThe study was aimed to measure serum levels of neopterin and calprotectin in patients with FMF in the attack-free period.
methodsA total of 160 participants were recruited from the rheumatology department in this single-center, case-control study. Individuals having the inclusion criteria were divided into healthy controls (n = 80) and FMF (n = 80). The laboratory data were acquired from the electronic registration database. Serum calprotectin and neopterin were measured with ELISA test kits. FMF patients and healthy controls' laboratory findings were compared.
resultsFMF patients' serum red cell distribution width (RDW), calprotectin, and neopterin values were significantly higher compared to healthy controls. There were no statistically significant differences between calprotectin and neopterin regarding gender, family history, and colchicine response of the FMF patients.
conclusionsCalprotectin, neopterin, and RDW can be valuable marker candidates to be used in the follow-up of subclinical inflammation in FMF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.